LJPC
LJPC Articles
Despite the wild ride the markets have taken, the faith of insiders certainly has not been shaken. It is indeed a positive to see insiders buying shares at current levels.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include CenturyLink, Gold Fields, Papa John's, Priceline, SolarCity, Tesla Motors and Unisys.
Published:
Last Updated:
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday include Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce,com, Tesla and Yelp.
Published:
Last Updated:
La Jolla Pharmaceuticals has announced the pricing of an underwritten offering of 2.55 million shares of its common stock.
Published:
The overwhelming cascade of insider buyers should come as no surprise, given the huge drops in the market over the past week and a half.
Published:
La Jolla Pharmaceutical has received an analyst call that implies a potential doubling of its shares.
Published:
One would expect that insiders looking to add to their positions would wait for a downturn in the market. That wasn’t the case this past week.
Published:
Source: ThinkstockStocks seem to be migrating from a tired bull market phase into a phase of volatility. It is also a phase where broad-based upside might not be an automatic assumption going...
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street analysts on Monday, August 4, 2014. They include Alcatel-Lucent, AEP, Chubb, Chevron, Halcon and Noble.
Published:
La Jolla Pharmaceutical shares surged after the micro-cap biotech said late Monday that its study for a chronic kidney disease treatment showed a statistically significant improvement.
Published:
We have run a watch list of companies under their own strategic review, and the number of biotech (or grouped with biotech) stocks under this description is just staggering.  We published a full...
Published:
Last Updated:
La Jolla Pharmaceutical Company (NASDAQ: LJPC) has been more than just a troubled biotech. It has even been considered an at-risk entity by some traders after it had been down more than 90% at one...
Published:
Last Updated:
Biogen Idec (NASDAQ: BIIB) is sliding marginally despite reported earnings today that showed a 23% increase in earnings riding on sales growth on Avonex and Rituxan. The earnings beat estimates and...
Published: